WO2005030985A3 - Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases - Google Patents

Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases Download PDF

Info

Publication number
WO2005030985A3
WO2005030985A3 PCT/GB2004/004103 GB2004004103W WO2005030985A3 WO 2005030985 A3 WO2005030985 A3 WO 2005030985A3 GB 2004004103 W GB2004004103 W GB 2004004103W WO 2005030985 A3 WO2005030985 A3 WO 2005030985A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
metabolic diseases
elongation
amino acid
fatty acids
Prior art date
Application number
PCT/GB2004/004103
Other languages
French (fr)
Other versions
WO2005030985A2 (en
Inventor
Wilde Gert Jules Hector De
Michael John Scott Saunders
Original Assignee
Devgen Nv
Wilde Gert Jules Hector De
Michael John Scott Saunders
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322493A external-priority patent/GB0322493D0/en
Application filed by Devgen Nv, Wilde Gert Jules Hector De, Michael John Scott Saunders filed Critical Devgen Nv
Publication of WO2005030985A2 publication Critical patent/WO2005030985A2/en
Publication of WO2005030985A3 publication Critical patent/WO2005030985A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to methods for the identification and/or the development of compounds that can be used to prevent and/or to treat metabolic diseases, and to the use of amino acid sequences that are involved in the elongation of fatty acids in such methods. The invention also relates to compounds that have been identified and/or developed using said methods, to pharmaceutical compositions that contain such compounds, and to the use of said compounds in the preparation of pharmaceutical compositions, in particular of pharmaceutical compositions for the prevention and/or treatment of metabolic diseases. The invention further relates to compounds that can interact with amino acid sequences that are involved in the elongation of fatty acids, to pharmaceutical compositions that contain such compounds, and to the use of said compounds in the preparation of pharmaceutical compositions, in particular of pharmaceutical compositions for the prevention and/or treatment of metabolic diseases.
PCT/GB2004/004103 2003-09-25 2004-09-24 Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases WO2005030985A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50597003P 2003-09-25 2003-09-25
GB0322493.8 2003-09-25
GB0322493A GB0322493D0 (en) 2003-09-25 2003-09-25 Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic dise
US60/505,970 2003-09-25

Publications (2)

Publication Number Publication Date
WO2005030985A2 WO2005030985A2 (en) 2005-04-07
WO2005030985A3 true WO2005030985A3 (en) 2005-11-17

Family

ID=34395445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004103 WO2005030985A2 (en) 2003-09-25 2004-09-24 Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases

Country Status (1)

Country Link
WO (1) WO2005030985A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532150A1 (en) 2003-07-11 2005-01-20 Banyu Pharmaceutical Co., Ltd. Method of evaluating compound efficacious in treating obesity
FR2903998B1 (en) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc MODULATORS OF ELOVL5 IN THE TREATMENT OF ACNE OR HYPERSEBORRHEA
CN112367971A (en) 2018-06-11 2021-02-12 加利福尼亚大学董事会 Demethylation for the treatment of ocular diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (en) * 1999-06-14 2000-12-21 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
WO2002062974A2 (en) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein
WO2003019146A2 (en) * 2001-08-29 2003-03-06 Xenon Genetics Inc. High throughput screening assays using fatty acid synthetic enzymes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (en) * 1999-06-14 2000-12-21 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
WO2002062974A2 (en) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein
WO2003019146A2 (en) * 2001-08-29 2003-03-06 Xenon Genetics Inc. High throughput screening assays using fatty acid synthetic enzymes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOON Y-A ET AL: "Identification of a Mammalian Long Chain Fatty Acyl Elongase Regulated by Sterol Regulatory Element-binding Proteins", JOURNAL OF BIOLOGICAL CHEMISTRY 30 NOV 2001 UNITED STATES, vol. 276, no. 48, 30 November 2001 (2001-11-30), pages 45358 - 45366, XP002963525, ISSN: 0021-9258 *
MOON YOUNG-AH ET AL: "Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 9, 28 February 2003 (2003-02-28), pages 7335 - 7343, XP002316434, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2005030985A2 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
DE602004016729D1 (en) 1-PHENYLALKANCARBONIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
MA28935B1 (en) PREPARATION AND USE OF BIPHENYL-4-YL CARBONYLAMINO ACID DERIVATIVES IN THE TREATMENT OF OBESITY
UY27438A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES AN OLIGÓMERO-PHARMACO INSULIN CONJUGATE, METHOD TO TREAT INSULIN DEFICIENCY IN A SUBJECT, METHOD FOR PROVIDING A PHARMACEUTICAL COMPOSITION.
BRPI0514420A (en) peptide, variant thereof, or a pharmaceutically acceptable salt thereof, composition, use of a peptide or peptide variant, substrate, and methods of treating or preventing a microbial infection, and treating a wound in an individual
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
EP1633722A4 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
ATE320803T1 (en) METHOD FOR TREATING ALZHEIMER'S DISEASE
WO2003039540A3 (en) D-amino acid oxidase inhibitors for learning and memory
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009100513A3 (en) Peptide des-[asp1]-[ala1], angi0tensin-(1 -7) agonist and pharmaceutical compounds for the treatment of diseases
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
EP2322186A3 (en) Methods and immune modulatory nucleic acid compositions for preventing and treating disease
WO2005034889A3 (en) Method for imparting artificial tan to human skin
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
BR0309406A (en) Pharmaceutical composition, preparation process, kit and methods for treating obesity, use of lipase composition and inhibitor, lipase inhibitor and glucomannan or konjac and their use and method of treatment
WO2005020970A3 (en) Protease inhibitor compositions for prevention and treatment of skin conditions
WO2005030985A3 (en) Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase